VistaGen Therapeutics, Inc. EBT margin

EBT margin of VTGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBT margin growth rates and interactive chart. The Earnings before tax margin. Calculated as earnings before tax divided by revenue. Measures the profitability of a company after all expenses are paid but before taxes. This is useful to compare various companies in an industry that might have different tax regimes or tax rates.


Highlights and Quick Summary

  • EBT margin for the quarter ending December 30, 2020 was -1689.64% (a 71.14% increase compared to previous quarter)
  • Year-over-year quarterly EBT margin decreased by -Infinity%
  • Annual EBT margin for 2020 was 0.0% (a NaN% decrease from previous year)
  • Annual EBT margin for 2019 was 0.0% (a NaN% decrease from previous year)
  • Annual EBT margin for 2018 was 0.0% (a -100.0% decrease from previous year)
  • Twelve month EBT margin ending December 30, 2020 was -714.33% (a 2.85% increase compared to previous quarter)
  • Twelve month trailing EBT margin decreased by -Infinity% year-over-year
Trailing EBT margin for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
-714.33% -694.51% 0.0% 0.0%
Visit stockrow.com/VTGN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBT margin of VistaGen Therapeutics, Inc.

Most recent EBT marginof VTGN including historical data for past 10 years.

Interactive Chart of EBT margin of VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. EBT margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -1689.64% -987.31% 0.0% 0.0% 0.0%
2019 0.0% 0.0% 0.0% 0.0% 0.0%
2018 0.0% 0.0% 0.0% 0.0% 0.0%
2017 0.0% 0.0% 0.0% 0.0% -820.25%
2016 -211.08% 0.0% 0.0% 0.0% 0.0%
2015 0.0% 0.0% 0.0% 0.0% 0.0%
2014 0.0% 0.0% 0.0% 0.0% 0.0%
2013 0.0% 0.0% 0.0% 0.0% -6428.64%
2012 0.0% 0.0% -910.18% -648.75% -909.54%
2011 -187504.17% -713.34% -434.46% -1.5% -457.78%
2010 -392.92% -133.75% 0.0%

Business Profile of VistaGen Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.